Colistin

• Description:

  Colistin is an orally active polypeptide antibiotic. Colistin has excellent activity against various Gram-negative rod-shaped bacteria, including multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. Colistin is associated with nephrotoxicity. Colistin can be used for the research of infections caused by Gram-negative bacilli[1][2].

• Product Name Alternative:

  Polymyxin E

• UNSPSC:

  12352100

• Hazard Statement:

  H315, H319, H320

• Target:

  Antibiotic; Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/colistin.html

• Solubility:

  H2O : 100 mg/mL (ultrasonic)

• Smiles:

  [H][C@@]([C@@H](C)O)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@@H](N1)CCN)=O)CC(C)C)=O)CC(C)C)=O)CCN)=O)CCN)=O)C(NCC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CCC[R])=O)CCN)=O)[C@@H](C)O)=O)CCN)=O)C1=O)=O.[C]C(C)C.[C][C@H](CC)C.[R:].[R:].[ColistinB].[ColistinA]

• Molecular Weight:

  1169.50

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Silpak Biswas, et al. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012 Aug;10 (8) :917-34. |[2]Jian Li, et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. |[3]Michael T Eadon, et al. Cell cycle arrest in a model of colistin nephrotoxicity. Physiol Genomics. 2013 Oct 1;45 (19) :877-88.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Animal Diseases. 2024 Apr 3.|Antimicrob Agents Chemother. 2025 Aug 6;69 (8) :e0037925.|Cell Host Microbe. 2024 May 13:S1931-3128 (24) 00137-9.|Dev Cell. 2025 May 15:S1534-5807 (25) 00287-4.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|Int Immunopharmacol. 2025 May 21:159:114888.|Microorganisms. 2024 Mar 13;12 (3) :575.|Vet Microbiol. 2024 May:292:110046.|Adv Sci (Weinh) . 2020 Jul 21;7 (17) :2001374.|Anim Dis. 2021;1 (1) :26.|Arthritis Res Ther. 2025 Jul 7;27 (1) :137.|bioRxiv. 2025 January 19.|bioRxiv. 2025 January 25.|Cell Host Microbe. 2025 Jun 11;33 (6) :915-931.e9.|Cell Mol Gastroenterol Hepatol. 2025 Feb 7:101474.|Clin Microbiol Infect. 2020 Sep;26 (9) :1264-1265.|Dev Cell. 2025 May 15:S1534-5807 (25) 00287-4.|Hum Exp Toxicol. 2021 Oct;40 (10) :1767-1780.|J Antibiot (Tokyo) . 2019 Aug;72 (8) :600-604.|J Antibiot (Tokyo) . 2025 Mar;78 (4) :265-273.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Nat Commun. 2024 Sep 10;15 (1) :7914.|Patent. US20200101105A1.|PLoS One. 2025 Jul 10;20 (7) :e0328167.|Sci Rep. 2025 May 8;15 (1) :16114.

• CAS Number:

  [1066-17-7]